Article
Immunology
Noe Juvenal Mendoza-Ramirez, Julio Garcia-Cordero, Sandra Paola Martinez-Frias, Daniela Roa-Velazquez, Rosendo Luria-Perez, Jose Bustos-Arriaga, Jesus Hernandez-Lopez, Carlos Cabello-Gutierrez, Joaquin Alejandro Zuniga-Ramos, Edgar Morales-Rios, Sonia Mayra Perez-Tapia, Martha Espinosa-Cantellano, Leticia Cedillo-Barron
Summary: This study analyzes the combination of two SARS-CoV-2 viral antigens and finds that immunization with a combination of S1 or RBD and the N protein can elicit a stronger immune response. The sera from immunized mice can recognize different variants of SARS-CoV-2. This study identifies potential antigens for the second generation of COVID-19 vaccines.
Article
Immunology
Haitao Liu, Chenliang Zhou, Jiao An, Yujiao Song, Pin Yu, Jiadai Li, Chenjian Gu, Dongdong Hu, Yuanxiang Jiang, Lingli Zhang, Chuanqi Huang, Chao Zhang, Yunqi Yang, Qianjun Zhu, Dekui Wang, Yuqiang Liu, Chenyang Miao, Xiayao Cao, Longfei Ding, Yuanfei Zhu, Hua Zhu, Linlin Bao, Lingyun Zhou, Huan Yan, Jiang Fan, Jianqing Xu, Zhongyu Hu, Youhua Xie, Jiangning Liu, Ge Liu
Summary: The researchers have developed a recombinant vaccine against SARS-CoV-2, which showed strong immunogenicity in animal studies, inducing robust antibody responses and T cell responses. The vaccine also demonstrated cross-neutralization activity against various variants, significantly reducing viral loads and lung inflammation.
Article
Biochemistry & Molecular Biology
Shahram Nazarian, Gholamreza Olad, Raziyeh Abdolhamidi, Mohammad Javad Motamedi, Rouhollah Kazemi, Emad Kordbacheh, Alireza Felagari, Hanieh Olad, Ali Ahmadi, Alireza Bahiraee, Parisa Farahani, Leila Haghighi, Faezeh Hassani, Vahideh Hajhassan, Mona Nadi, Abdolkarim Sheikhi, Jafar Salimian, Jafar Amani
Summary: In this study, a candidate vaccine based on SARS-CoV-2 antigens was designed and evaluated for its safety and immunogenicity. The results showed that RBD with Alum adjuvant produced a strong immune response and the ability to neutralize the virus in mice, rabbits, and primates.
MOLECULAR IMMUNOLOGY
(2022)
Article
Immunology
Tripti Shrivastava, Balwant Singh, Zaigham Abbas Rizvi, Rohit Verma, Sandeep Goswami, Preeti Vishwakarma, Kamini Jakhar, Sudipta Sonar, Shailendra Mani, Sankar Bhattacharyya, Amit Awasthi, Milan Surjit
Summary: Researchers have successfully designed the SARS-CoV-2 spike protein fragment 330-526 as a potential vaccine candidate, showing stability and strong immune response. Immunization with RBD generated high titer humoral responses, cytotoxic T cells, and neutralizing antibodies in mice.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Erika Rudi, Pablo Martin Aispuro, Eugenia Zurita, Maria M. Gonzalez Lopez Ledesma, Daniela Bottero, Juan Malito, Magali Gabrielli, Emilia Gaillard, Matthew Stuible, Yves Durocher, Andrea V. Gamarnik, Andres Wigdorovitz, Daniela Hozbor
Summary: The study evaluated the immune capacity of vaccine candidates based on different SARS-CoV-2 variants and found that the single S protein from the ancestral Wuhan virus displayed the highest antibody levels and neutralizing antibody titers against different variants. Additionally, this formulation also induced various immune cell responses and antibody levels. When used as a booster dose, it enhanced the immune response against different S protein variants.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Mayanka Awasthi, Anthony Macaluso, Dawn Myscofski, Jon Prigge, Fusataka Koide, Ryan S. Noyce, Siobhan Fogarty, Helen Stillwell, Scott J. Goebel, Bruce Daugherty, Farooq Nasar, Sina Bavari, Seth Lederman
Summary: This study evaluated the immunogenicity and efficacy of the synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate TNX-1800 in nonhuman primate species challenged with SARS-CoV-2. The vaccine generated both humoral and cellular responses and showed rapid clearance of the virus. Further studies will assess its efficacy against emerging variants and its safety in humans.
Article
Multidisciplinary Sciences
So-Hee Hong, Hanseul Oh, Yong Wook Park, Hye Won Kwak, Eun Young Oh, Hyo-Jung Park, Kyung Won Kang, Green Kim, Bon-Sang Koo, Eun-Ha Hwang, Seung Ho Baek, Hyeong-Jun Park, Yu-Sun Lee, Yoo-Jin Bang, Jae-Yong Kim, Seo-Hyeon Bae, Su Jeen Lee, Ki-Weon Seo, Hak Kim, Taewoo Kwon, Ji-Hwan Kim, Seonghwan Lee, Eunsom Kim, Yeonhwa Kim, Jae-Hak Park, Sang-In Park, Marta Goncalves, Byung Mook Weon, Haengdueng Jeong, Ki Taek Nam, Kyung-Ah Hwang, Jihye Kim, Hun Kim, Sang-Myeong Lee, Jung Joo Hong, Jae-Hwan Nam
Summary: A novel subunit vaccine was developed and shown to be effective in rodents and nonhuman primates. The addition of SARS-CoV-2 nucleocapsid protein enhanced the immune response of the vaccine, supporting the further development of RBD-P2 as a candidate vaccine against SARS-CoV-2.
Article
Medical Laboratory Technology
Faezeh Noorabad Ghahroodi, Saeed Khalili, Mohammad Javad Rasaee
Summary: This study demonstrates the potential use of truncated recombinant proteins derived from the spike protein as vaccine candidates against SARS-CoV-2. In silico, in vitro, and in vivo experiments show that these proteins can stimulate neutralizing antibody responses.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2022)
Article
Immunology
Leandro Nunez-Munoz, Gabriel Marcelino-Perez, Berenice Calderon-Perez, Miriam Perez-Saldivar, Karla Acosta-Virgen, Hugo Gonzalez-Conchillos, Brenda Vargas-Hernandez, Ana Olivares-Martinez, Roberto Ruiz-Medrano, Daniela Roa-Velazquez, Edgar Morales-Rios, Jorge Ramos-Flores, Gustavo Torres-Franco, Diana Pelaez-Gonzalez, Jorge Fernandez-Hernandez, Martha Espinosa-Cantellano, Diana Tapia-Sidas, Jose Abrahan Ramirez-Pool, America Padilla-Viveros, Beatriz Xoconostle-Cazares
Summary: This study demonstrated the potential usefulness of antigens based on the non-N-glycosylated region of RBD from SARS-CoV-2 by expressing and testing potential antigens NG06 and NG19 in different animal models to induce immune responses.
Article
Virology
Jafar Salimian, Ali Ahmadi, Jafar Amani, Gholamreza Olad, Raheleh Halabian, Ali Saffaei, Masoud Arabfard, Mojtaba Nasiri, Shahram Nazarian, Hassan Abolghasemi, Gholamhossein Alishiri
Summary: The study evaluated the safety and immunogenicity of a recombinant receptor-binding domain (RBD)-based protein subunit vaccine (Noora vaccine) against COVID-19. The vaccine showed acceptable safety without severe adverse events and significant seroconversion in both humoral and cellular immunity.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Immunology
Priyanka Shah, Gabriela A. Canziani, Erik P. Carter, Irwin Chaiken
Summary: Research suggests that while current focus is on studying the S1 receptor-binding domain in COVID-19 vaccines and therapies, exploring the potential benefits of the more conserved S2 subunit should not be overlooked. Utilizing S2 in treatments and vaccines may enhance the neutralizing potential of antibodies, strengthen memory B-cell and T-cell responses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Daniela Bottero, Erika Rudi, Pablo Martin Aispuro, Eugenia Zurita, Emilia Gaillard, Maria M. Gonzalez Lopez Ledesma, Juan Malito, Matthew Stuible, Nicolas Ambrosis, Yves Durocher, Andrea V. Gamarnik, Andres Wigdorovitz, Daniela Hozbor
Summary: This study evaluated the effectiveness of a heterologous three-dose vaccination schedule against Omicron BA.1 variant infection and found that mRNA-based vaccines performed the best in enhancing both humoral and cellular immune responses. Heterologous schedules showed better immunological outcomes for AZD1222-based primary series compared to homologous three-dose AZD1222 regimen. All tested schedules induced immune cell populations and protected mice from intranasal challenge with Omicron BA.1.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Yuling Han, Jiaxin Yang, Danshuang He, Yang Feng, Xiaoman Liu, Yu Min, Shenghao Fan, Guobing Yin, Daixing Hu
Summary: This study assessed the safety and immunogenicity of SARS-CoV-2 vaccines in patients with thyroid cancer. The results showed that SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients. However, the duration of immune response is shorter in these patients compared to healthy adults. Therefore, a booster vaccination may be recommended earlier for thyroid cancer patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Virology
Hung-Chun Liao, Min-Syuan Huang, Fang-Feng Chiu, Kit Man Chai, Ching-Len Liao, Suh-Chin Wu, Hsin-Wei Chen, Shih-Jen Liu
Summary: This study reports a novel COVID-19 vaccine that combines recombinant S protein with a DNA vaccine. The combination vaccine induces strong T-cell immune response and enhances immune indicators such as antibody titers. In animal experiments, hamsters vaccinated with the combination vaccine showed no weight loss and had low viral load in the lungs, indicating the important role of this vaccine in disease control.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Ting Zhang, Ningchen Zheng, Zhirong Wang, Xuemei Xu
Summary: The multimeric form of SARS-CoV-2 S protein receptor-binding domain (RBD) shows better immunogenicity and induces higher levels of neutralizing antibody responses. A recombinant protein, 2RBDpLC, was constructed by fusing RBD single-chain dimer with a trimerization motif and introducing a cysteine at the C-terminus. It forms RBD dodecamers through trimerization motif and intermolecular disulfide bonds, and exhibits promising potential as a vaccine candidate with the ability to generate cross-neutralizing antibodies against Delta and Omicron variants.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Multidisciplinary Sciences
Laura Ulitzky, Manuel M. Lafer, Mark A. KuKuruga, Erica Silberstein, Nicoleta Cehan, Deborah R. Taylor
Article
Infectious Diseases
Eleni Marie Rettig, Carole Fakhry, Anne F. Rositch, Anne E. Burke, Kathryn Chang, Michelle I. Silver, Raphael Viscidi, Patti Gravitt
SEXUALLY TRANSMITTED DISEASES
(2016)
Article
Infectious Diseases
Jianchun Xiao, Ye Li, Emese Prandovszky, Geetha Kannan, Raphael P. Viscidi, Mikhail V. Pletnikov, Robert H. Yolken
PLOS NEGLECTED TROPICAL DISEASES
(2016)
Article
Virology
Rosie T. Jiang, Joshua W. Wang, Shiwen Peng, Tsui-Chin Huang, Chenguang Wang, Fabiana Cannella, Yung-Nien Chang, Raphael P. Viscidi, Simon R. A. Best, Chien-Fu Hung, Richard B. S. Roden
JOURNAL OF VIROLOGY
(2017)
Article
Immunology
Seweryn Bialasiewicz, Gareth Hart, Kimberly Oliver, Shruti P. Agnihotri, Igor J. Koralnik, Raphael Viscidi, Michael D. Nissen, Theo P. Sloots, Michael T. Burke, Nicole M. Isbel, John Burke
Article
Immunology
Francesca Rossi, Luca Prosperini, Nicola De Rossi, Ruggero Capra, Daniela Rivanera, Xiuhong Li, Paola Cinque, Laura Passeri, Carlo Pozzilli, Raphael Viscidi
Article
Oncology
Daniel C. Beachler, Ligia A. Pinto, Troy J. Kemp, Alan G. Nyitray, Allan Hildesheim, Raphael Viscidi, John Schussler, Aimee R. Kreimer, Anna R. Giuliano
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2018)
Article
Immunology
Ye Li, Raphael P. Viscidi, Geetha Kannan, Ross McFarland, Mikhail Pletnikov, Emily G. Severance, Robert H. Yolken, Jianchun Xiao
INFECTION AND IMMUNITY
(2018)
Article
Immunology
Jianchun Xiao, Ye Li, Robert H. Yolken, Raphael P. Viscidi
JOURNAL OF NEUROIMMUNOLOGY
(2018)
Article
Multidisciplinary Sciences
Erica Silberstein, Carylinda Serna, Stenio Perdigao Fragoso, Rana Nagarkatti, Alain Debrabant
Article
Multidisciplinary Sciences
David DeWolfe, Jinal Gandhi, Matthew R. Mackenzie, Thomas A. Broge, Evelyn Bord, Amaara Babwah, Didier A. Mandelbrot, Martha Pavlakis, Francesca Cardarelli, Raphael Viscidi, Anil Chandraker, Chen S. Tan
Article
Immunology
Ye Li, Emily G. Severance, Raphael P. Viscidi, Robert H. Yolken, Jianchun Xiao
INFECTION AND IMMUNITY
(2019)
Article
Oncology
Brian W. Simons, Fabiana Cannella, Dayana T. Rowley, Raphael P. Viscidi
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2020)
Article
Virology
Carolina Scagnolari, Fabiana Cannella, Alessandra Pierangeli, Rebecca Mellinger Pilgrim, Guido Antonelli, Dayana Rowley, Margaret Wong, Simon Best, Deyin Xing, Richard B. S. Roden, Raphael Viscidi
JOURNAL OF VIROLOGY
(2020)
Article
Microbiology
Erica Silberstein, Kwang Sik Kim, David Acosta, Alain Debrabant
Summary: This study utilized a 3D cell culture model to recreate the human placental environment, demonstrating that 3D-cultured JEG-3 cells have reduced susceptibility to T. cruzi infection and release paracrine factors that prevent infection of non-trophoblastic cell lines. This in vitro model may help understand how parasites bypass the human placental barrier and could be used to evaluate therapeutics for reducing congenital Chagas Disease.
FRONTIERS IN MICROBIOLOGY
(2021)